JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a
commercial-stage diagnostics company, today announced the appointment of Franz Walt to its board of directors effective February
19, 2018
Mr. Walt joins Quotient’s board of directors with over 29 years of experience in leadership roles at two of the
largest, most influential healthcare companies, Siemens Healthineers and Roche, and serves as an expert advisor on the in-vitro
diagnostics industry to manufacturing companies and private equity firms. His career has focused on business turnaround and market
expansion, emphasizing innovation, strategic alliances, quality and commercialization. In December 2017 Mr. Walt retired as
President of Siemens Healthineers, Laboratory Diagnostics, where he served a President since 2014. While at Roche, Mr. Walt
served 8 years as a member of the Roche Diagnostics Executive Committee. His executive positions included CEO at Roche Diagnostics
GmbH in Mannheim, Germany and positions of increasing responsibility in pharma and IVD. Mr. Walt served as a board member of the
AdvaMed DX industry association, where he actively contributed to shape healthcare policy in diagnostic testing to improve patient
health. Mr. Walt holds an M.B.A. from the City University of Bellevue (Washington).
“We are excited to have Franz join us during such a critical period as we work towards the commercial launch of
MosaiQ,” said Paul Cowan, Quotient’s Chairman and Chief Executive Officer. “His vast experience in leading laboratory diagnostic
companies through periods of high growth, including the launch of major new diagnostics platforms, will be invaluable. This
expertise will also be invaluable as we seek to broaden the diagnostics applications addressed by MosaiQ.”
“I am excited to be joining the Board of Quotient at this important time in its progression towards the
commercial launch of MosaiQ,” said Franz Walt. “For some time now I have been monitoring the progress of MosaiQ, which is clearly a
ground-breaking technology that will deliver major work flow efficiencies to transfusion laboratories worldwide while improving
patient care. I also believe MosaiQ has a very interesting future as a diagnostics platform beyond the field of transfusion
diagnostics.”
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient
care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological
and molecular disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to address the $3.4 billion
global transfusion diagnostics market. The Company's operations are based in Switzerland, Scotland and the US.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries
in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — chris.lindop@quotientbd.com; +0799 61 69 38